-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
PACIFIC is a placebo-controlled phase III clinical trial.
PACIFIC is a placebo-controlled phase III clinical trial.
A total of 713 patients were randomized; 158/713 (22.
A total of 713 patients were randomized; 158/713 (22.
The PFS analysis was performed for the first time on February 13, 2017.
PFS
The first OS analysis was performed on March 22, 2018.
The first OS analysis was performed on March 22, 2018.
OS
Regardless of age, the ORR of the durvalumab group was higher than that of the placebo group
Regardless of age, the ORR of the durvalumab group was higher than that of the placebo group
Efficacy evaluation
Consistent with the ITT population, the durvalumab group received a lower proportion of subsequent anti-tumor treatments, patients ≥70 years old (durvalumab, 36.
Consistent with the ITT population, the durvalumab group received a lower proportion of subsequent anti-tumor treatments, patients ≥70 years old (durvalumab, 36.
Patients in the durvalumab group ≥70 years of age experienced a higher proportion of grade 3/4 adverse events (durvalumab, 41.
In summary, the elderly patients with unresectable stage III non-small cell lung cancer (NSCLC) still benefit from Durvalumab maintenance treatment after concurrent radiotherapy and chemotherapy, and the toxicity is controllable and tolerable
Original source:
Mark A.
Socinski, Mustafa Ozgüro˘ glu, Augusto Villegas, et al.
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Clinical Lung Cancer.
2021.
DOI: https:// doi.
org/10.
1016/j.
cllc.
2021.
05.
009.
Socinski, Mustafa Ozgüro˘ glu, Augusto Villegas, et al.
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients with Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Clinical Lung Cancer.
2021.
DOI: https:// doi.
org/10.
1016/j.
cllc.
2021.
05.
009.
Leave a message here